- Home
- FISI vs AVXL Comparison
FISI vs AVXL Comparison
Compare FISI & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- AVXL
- Stock Information
- Founded
- FISI 1817
- AVXL 2004
- Country
- FISI United States
- AVXL United States
- Employees
- FISI N/A
- AVXL N/A
- Industry
- FISI Major Banks
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FISI Finance
- AVXL Health Care
- Exchange
- FISI Nasdaq
- AVXL Nasdaq
- Market Cap
- FISI 416.4M
- AVXL 771.1M
- IPO Year
- FISI 1999
- AVXL N/A
- Fundamental
- Price
- FISI $27.90
- AVXL $9.11
- Analyst Decision
- FISI Hold
- AVXL Strong Buy
- Analyst Count
- FISI 2
- AVXL 2
- Target Price
- FISI $22.00
- AVXL $43.00
- AVG Volume (30 Days)
- FISI 43.5K
- AVXL 1.8M
- Earning Date
- FISI 10-24-2024
- AVXL 12-03-2024
- Dividend Yield
- FISI 4.30%
- AVXL N/A
- EPS Growth
- FISI N/A
- AVXL N/A
- EPS
- FISI 3.17
- AVXL N/A
- Revenue
- FISI $216,605,000.00
- AVXL N/A
- Revenue This Year
- FISI N/A
- AVXL N/A
- Revenue Next Year
- FISI $6.94
- AVXL N/A
- P/E Ratio
- FISI $8.80
- AVXL N/A
- Revenue Growth
- FISI 9.25
- AVXL N/A
- 52 Week Low
- FISI $16.29
- AVXL $3.25
- 52 Week High
- FISI $28.14
- AVXL $10.45
- Technical
- Relative Strength Index (RSI)
- FISI 62.80
- AVXL 68.52
- Support Level
- FISI $26.00
- AVXL $7.18
- Resistance Level
- FISI $28.12
- AVXL $9.39
- Average True Range (ATR)
- FISI 0.74
- AVXL 0.86
- MACD
- FISI 0.09
- AVXL 0.04
- Stochastic Oscillator
- FISI 93.85
- AVXL 59.02
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.